Drug intelligence / Profile preview

QR437

Development stage: Discontinued
Lead developer: Quigley Pharma
Modality: Small Molecules

Overview

QR437 is an experimental virucidal compound developed by Quigley Pharma, a subsidiary of The Quigley Corporation. During its pre-clinical development phase in the mid-2000s, the drug was investigated for its potential to neutralize or inhibit the replication of the Human Immunodeficiency Virus (HIV). Research activities included in vitro experiments to characterize its virucidal and virustatic properties. However, the specific biological target and chemical structure were never publicly disclosed, and the project has since been discontinued without advancing to clinical trials.

Beyond the preview

Go deeper on QR437.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QR437.

Explore the full profile